Skip to main content
ConductScienceScienceDex
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

546

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

546 results for “Predictive biomarkers”

Learn how ShareScore rates datasets ↗
zenodo40/100

Dataset of clinical biomarkers for prediction of the arboviral infection severity using SIMON analysis

<p>The SISA dataset was used for the identification of clinical biomarkers that can predict the severity of the arboviral infection severity using SIMON analysis, as described (<a href="https://doi.org/10.1101/2020.08.16.252767">https://doi.org/10.1101/2020.08.16.252767</a>). The dataset contains clinical data from 543 individuals hospitalized due to the arboviral infection with Dengue, chikungunya, or Zika viruses from a surveillance study in Ecuador collected from 2013 to 2017 (Suppy et al., 2020, doi: 10.1371/journal.pntd.0007969). In the SISA dataset, we have excluded columns with high level of missing values (pregnancy, <em>WomPreg</em> and complete blood count test which was not performed for all donors and includes columns: <em>PLT_count, Lymphocytes, CBC_N%, WBC_calc </em>and<em> CBC_HCT</em>). &nbsp;Additionally, 9 donors with missing values were removed and SIMON analysis was performed with this final dataset.</p>

opencc-by-4.0Oct 2020View details →
zenodo40/100

Fecal-bbu-genes-quantification-predicts-L-carnitine-mediated-TMAO-production-and-serves-as-a-biomarker-for-precision-nutrition-code-20231201

<p>Custom code related to the original research article "Fecal bbu genes quantification predicts L-carnitine-mediated TMAO production and serves as a biomarker for precision nutrition"</p>

opencc-by-4.0Nov 2023View details →
ClinicalTrials.gov40/100

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

ClinicalTrials.gov study NCT04774926. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
zenodo36/100

Basophils as a predictive hematological biomarker of canine visceral leishmaniasis in the treatment with miltefosine

<p><strong>BACKGROUND:</strong> Basophils are initiators of the Th2 response related to the progression of canine visceral leishmaniasis (CanL). Miltefosine has been presented as an alternative in treatment due to its leishmanicide and immunomodulatory effects. Many blood cells have been used as predictive biomarkers, but none of them focused on the immunomodulatory action of miltefosine in the different stages of the disease.</p> <p><strong>OBJECTIVE:</strong> Identifying the predictive hematological biomarkers in dogs with visceral leishmaniasis treated with miltefosine.</p> <p><strong>METHODS:</strong> The animals were divided into three groups: sick dogs; infected dogs, dogs exposed. The animals were submitted to differential blood cell count and CanL diagnosis, through DPP, ELISA and qPCR. The groups were monitored from the time zero (T0) before treatment, and the times twenty (T20) and thirty (T30) days after the beginning of &nbsp;treatment using miltefosine at a dose of 1mL/10kg per day for 28 days.</p> <p><strong>FINDINGS:</strong> Basophils showed an exponential increase in the infected and sick group with an increase of IgG, suggesting a Th2 response. In the exposed group there was reduction of basophils with increase in monocytes and IgG reduction, suggesting a Th1 response.</p> <p><strong>CONCLUSIONS:</strong> We suggest basophils as a predictive biomarker of immunomodulation in the treatment of CanL with miltefosine.</p> <p><strong>BACKGROUND:</strong> Basophils are initiators of the Th2 response related to the progression of canine visceral leishmaniasis (CanL). Miltefosine has been presented as an alternative in treatment due to its leishmanicide and immunomodulatory effects. Many blood cells have been used as predictive biomarkers, but none of them focused on the immunomodulatory action of miltefosine in the different stages of the disease.</p> <p><strong>OBJECTIVE:</strong> Identifying the predictive hematological biomarkers in dogs with visceral leishmaniasis treated with miltefosine.</p> <p><strong>METHODS:</strong> The animals were divided into three groups: sick dogs; infected dogs, dogs exposed. The animals were submitted to differential blood cell count and CanL diagnosis, through DPP, ELISA and qPCR. The groups were monitored from the time zero (T0) before treatment, and the times twenty (T20) and thirty (T30) days after the beginning of &nbsp;treatment using miltefosine at a dose of 1mL/10kg per day for 28 days.</p> <p><strong>FINDINGS:</strong> Basophils showed an exponential increase in the infected and sick group with an increase of IgG, suggesting a Th2 response. In the exposed group there was reduction of basophils with increase in monocytes and IgG reduction, suggesting a Th1 response.</p> <p><strong>CONCLUSIONS:</strong> We suggest basophils as a predictive biomarker of immunomodulation in the treatment of CanL with miltefosine.</p>

opencc-by-4.0Mar 2022View details →
zenodo36/100

Predictive modelling of brain metastasis risk and non-invasive biomarker detection using DNA methylation signatures

<p>Methylated&nbsp;cell-free DNA was&nbsp;sequenced for 123 BM plasma and compared to plasma methylomes&nbsp;from 107 gliomas, central nervous system (CNS)&nbsp;lymphomas (CNSL), and non-CNS&nbsp;tumor controls.&nbsp;Plasma methylome-based classifiers of BM from&nbsp;other entities were&nbsp;built in fifty 80% discovery set iterations of 92/123 BM&nbsp;samples. External publicly-available tissue methylation data on&nbsp;442 LUAD, 85&nbsp;BM, and 146 glioma/CNSL/control samples were acquired for validation and the&nbsp;remaining 31/123 BM&nbsp;plasma samples were used for additional validation.</p>

opencc-by-4.0Dec 2021View details →
zenodo36/100

Protein biomarkers for early predictions of hypoxic ischemic encephalopathy

<p>Perinatal asphyxia is a temporary interruption of oxygen availability that results in neonatal morbidity and mortality. The exact burden of perinatal asphyxia is unknown due to the lack of valid and accepted diagnostic criteria applicable to resource-limited settings. After sepsis, it is the second most important cause of neonatal death.&nbsp;Though there are tests available that can indicate whether an infant is suffering from birth asphyxia or not, they are not the gold standard. There is a dire need for early detection biomarkers for birth asphyxia so that the outcome of birth asphyxia can be avoided. Urinary and serum proteomics has rapidly developed and standard collection and experiment protocols are now available. With the help of the &lsquo;omics&rsquo; approach, we can speed up biomarker discovery and widely use it to facilitate diagnostic and therapeutic developments for many diseases. Some of the promising biomarkers found in urine and serum are&nbsp;APOC3,&nbsp;ORM1,&nbsp;SOD1,&nbsp;FABP1, and&nbsp;AZGP1.</p>

opencc-by-4.0Mar 2023View details →
dryad36/100

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

<p>PARP inhibitors (PARPis) have changed the treatment paradigm in BRCA-mutant high-grade serous ovarian carcinoma (HGSC). However, most patients eventually develop resistance to PARPis, highlighting an unmet need for novel therapeutic strategies. Using high-throughput drug screens, we identified ATR/CHK1 pathway inhibitors as cytotoxic, and further validated monotherapy activity of the CHK1 inhibitor (CHK1i), prexasertib, in PARPi-resistant BRCA-mutant HGSC cells and animal models. As a proof-of-concept trial, we conducted a phase II study of prexasertib in BRCA-mutant HGSC patients. The treatment was well-tolerated but yielded an objective response rate of 6% (1/17; 1 PR) in patients with prior PARPi treatment. Exploratory biomarker analyses revealed that replication stress and fork stabilization were associated with clinical benefit to CHK1i. In particular, overexpression of BLM, and CCNE1 overexpression or copy number gain/amplification were seen in patients deriving durable benefit from CHK1i. Our findings suggest replication fork–related biomarkers should be further evaluated for CHK1i sensitivity in HGSC.</p>

opencc-zeroJun 2023View details →
ClinicalTrials.gov36/100

Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock

ClinicalTrials.gov study NCT05824767. IPD Sharing: NO. Countries: 1. Publications: 17.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)

ClinicalTrials.gov study NCT02719184. IPD Sharing: YES. Countries: 12. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline

ClinicalTrials.gov study NCT06779487. IPD Sharing: NO. Countries: 1. Publications: 5.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response

ClinicalTrials.gov study NCT00694096. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

ClinicalTrials.gov study NCT03694912. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Using Biomarkers to Predict TB Treatment Duration

ClinicalTrials.gov study NCT02821832. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms

ClinicalTrials.gov study NCT02611206. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma

ClinicalTrials.gov study NCT07063758. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

ClinicalTrials.gov study NCT07349277. IPD Sharing: YES. Countries: 1. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Electroencephalographic Biomarker to Predict Postoperative Delirium

ClinicalTrials.gov study NCT05992506. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad36/100

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA-mutant ovarian cancer

Open the record for dataset details and reuse information.

publicJul 2023View details →
dryad36/100

Data from: A clockwork fish. Age-prediction using DNA methylation-based biomarkers in the European seabass

Open the record for dataset details and reuse information.

publicDec 2019View details →
dryad32/100

Predictive biomarkers of individual trajectories in elderly persons with subtle cognitive decline: APOE genotype data

<p>The mentalizing network (MN) treats social interactions based on our understanding of other people's intentions and includes the medial prefrontal cortex (mPFC), temporoparietal junction (TPJ), posterior cingulate cortex (PCC), precuneus (PC) and amygdala. Not all elders are equally affected by the aging-related decrease of mentalizing abilities. Personality has recently emerged as a strong determinant of functional connectivity in MN areas. However, its impact on volumetric changes across the mentalizing network in brain aging is still unknown. To address this issue, we explored the determinants of volume decrease in MN components including amyloid burden, personality, and APOE genotyping in a previously established cohort of 130 healthy elders with a mean follow-up of 54 months. Personality was assessed with the Neuroticism Extraversion Openness Personality Inventory-Revised. Regression models corrected for multiple comparisons were used to identify predictors of volume loss including time, age, sex, personality, amyloid load, presence of APOE epsilon 4 allele and cognitive evolution. In cases with higher Agreeableness scores, there were lower volume losses in posterior cingulate cortex (PCC), precuneus (PC) and amygdala bilaterally. This was also the case for right medial prefrontal cortex (mPFC) in elders displaying lower Agreeableness and Conscientiousness. In multiple regression models, the effect of Agreeableness was still observed in left PC and right amygdala and that of Conscientiousness in right mPFC volume loss (26.3% of variability, significant age, sex). Several Agreeableness (Modesty) and Conscientiousness (order, dutifulness, achievement striving and self-discipline) facets were positively related to increased volume loss in cortical components of the MN. In conclusion, these data challenge the beneficial role of higher levels of Agreeableness and Conscientiousness in old age showing that they are associated with an increased rate of volume loss within the mentalizing network.</p>

opencc-zeroOct 2020View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.